281 related articles for article (PubMed ID: 25888323)
1. Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer.
Lee CY; Shim HS; Lee S; Lee JG; Kim DJ; Chung KY
J Cardiothorac Surg; 2015 Mar; 10():44. PubMed ID: 25888323
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
Cox G; Jones JL; O'Byrne KJ
Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
[TBL] [Abstract][Full Text] [Related]
3. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
4. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9.
Sienel W; Polzer B; Elshawi K; Lindner M; Morresi-Hauf A; Vay C; Eder F; Passlick B; Klein CA
Mod Pathol; 2008 Sep; 21(9):1130-8. PubMed ID: 18567995
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer].
Honguero Martínez AF; Arnau Obrer A; Figueroa Almazán S; Martínez Hernández N; Guijarro Jorge R
Med Clin (Barc); 2014 May; 142(10):432-7. PubMed ID: 23948151
[TBL] [Abstract][Full Text] [Related]
6. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM
Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer.
Ishikawa S; Takenaka K; Yanagihara K; Miyahara R; Kawano Y; Otake Y; Hasegawa S; Wada H; Tanaka F
Clin Cancer Res; 2004 Oct; 10(19):6579-85. PubMed ID: 15475447
[TBL] [Abstract][Full Text] [Related]
10. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
[TBL] [Abstract][Full Text] [Related]
12. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer.
Sienel W; Hellers J; Morresi-Hauf A; Lichtinghagen R; Mutschler W; Jochum M; Klein C; Passlick B; Pantel K
Int J Cancer; 2003 Feb; 103(5):647-51. PubMed ID: 12494473
[TBL] [Abstract][Full Text] [Related]
14. High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection.
Chang PM; Yeh YC; Chen TC; Wu YC; Lu PJ; Cheng HC; Lu HJ; Chen MH; Chou TY; Huang CY
Ann Surg Oncol; 2013 Oct; 20(11):3648-54. PubMed ID: 23775407
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.
Cappuzzo F; Tallini G; Finocchiaro G; Wilson RS; Ligorio C; Giordano L; Toschi L; Incarbone M; Cavina R; Terracciano L; Roncalli M; Alloisio M; Varella-Garcia M; Franklin WA; Santoro A
Ann Oncol; 2010 Mar; 21(3):562-567. PubMed ID: 19767315
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer.
Ghio P; Cappia S; Selvaggi G; Novello S; Lausi P; Zecchina G; Papotti M; Borasio P; Scagliotti GV
Clin Lung Cancer; 2006 May; 7(6):395-400. PubMed ID: 16800965
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma.
Sun PL; Jin Y; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
Virchows Arch; 2013 Sep; 463(3):427-36. PubMed ID: 23907568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
